OpportunityAnalyzer: Vasculitis Report 2016 - Opportunity Analysis and Forecast 2014-2024 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024" report to their offering.

This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Beh├žet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively.

Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM.

Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.

Key Questions Answered

- How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?

- What opportunities remain in the market for new product entrants?

- With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?

- According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?

- What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?

Key Findings

- Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.

- Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.

- Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.

- With several major pharmaceutical companies involved in development of vasculitis products, the market will be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.

Companies Mentioned

  • AbbVie
  • J&J
  • BMS
  • Roche
  • Merck
  • GSK
  • Biogen
  • Genentech
  • Boehringer Ingelheim
  • Celltrion
  • Pfizer
  • Celgene
  • Sanofi
  • Eisai
  • Zydus Cadila
  • Mitsubishi Tanabe
  • Alvogen
  • Hospira
  • Mundipharma
  • Novartis
  • Baxter
  • UCB
  • Prometheus
  • Aspen
  • Ono
  • Eli Lilly
  • Chugaii
  • AstraZeneca
  • ChemoCentryx
  • Delenex
  • Sobi
  • Amgen

For more information visit http://www.researchandmarkets.com/research/x4rdvg/opportunityanalyze

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716